By Benjamin Horney ( January 18, 2017, 1:43 PM EST) -- Pharmaceutical giant Eli Lilly and Co. has agreed to buy migraine treatment developer CoLucid Pharmaceuticals Inc. for roughly $960 million, the companies said Wednesday, in a deal guided by legal advisers Weil Gotshal & Manges LLP and Faegre Baker Daniels....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.